Key result
Multi-omics approaches identify key molecular biomarkers and therapeutic targets for lupus nephritis prediction and treatment.
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is associated with significant morbidity and mortality of SLE patients. The pathogenesis of LN involves multiple factors, including genetic predisposition, epigenetic regulation and environmental interaction. Over the last decade, omics-based techniques have been extensively utilized for biomarker screening and a wide variety of variations which are associated with SLE and LN have been identified at the levels of genomics, transcriptomics and proteomics. These studies and discoveries have expanded our understanding of the molecular basis of the disease and are important for identification of potential therapeutic targets for disease prediction and early treatment. In this review, we summarize some of the recent studies targeted at the identification of LN-associated biomarkers using genomics and proteomic approaches.
No takes yet. Share an insight, caveat, or question.
Li et al. (2013) conducted a review in Lupus nephritis (systemic lupus erythematosus). Genomics, transcriptomics, and proteomics biomarker profiling was evaluated. Omics-based techniques (genomics, transcriptomics, and proteomics) have identified molecular biomarkers and potential therapeutic targets for lupus nephritis prediction and early treatment.
Synapse has enriched 5 related papers. Consider them for comparative context: